Shanghai Junshi Biosciences files list of directors with HKEX

Reuters03-13
<a href="https://laohu8.com/S/SHJBF">Shanghai Junshi Biosciences</a> files list of directors with HKEX

Junshi Biosciences filed a list of directors with the Hong Kong Stock Exchange naming Xiong Jun as chairman and legal representative and Li Ning as vice chairman. The filing listed Zou Jianjun as chief executive officer and general manager and Li Cong as co-chief executive officer. It also named Tang Yi as a non-executive director and listed independent non-executive directors Zhang Chun and Feng Xiaoyuan. The board committee table showed Xiong Jun as chair of the Strategic and ESG Committee and Zhang Chun as chair of the Audit Committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260313-12051885), on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment